Belgian Diabetes Registry Selected Research

HLA-DQ Antigens (HLA-DQ)

1/2018	Accelerated Progression to Type 1 Diabetes in the Presence of HLA-A24 and -B18 Is Restricted to Multiple Islet Autoantibody-Positive Individuals With Distinct HLA-DQ and Autoantibody Risk Profiles.
1/2017	Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes.
9/2013	In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A24 and HLA-B18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.
4/2013	HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.
12/2010	Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population.
10/2007	Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives.
8/2007	TNFa microsatellite polymorphism modulates the risk of type 1 diabetes in the Belgian population, independent of HLA-DQ.
1/2006	MICA is associated with type 1 diabetes in the Belgian population, independent of HLA-DQ.
7/2004	The rare HLA-DQA103-DQB102 haplotype confers susceptibility to type 1 diabetes in whites and is preferentially associated with early clinical disease onset in male subjects.
6/2002	Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Belgian Diabetes Registry Research Topics

Disease

24	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2021 - 08/2000
3	Disease Progression 11/2021 - 09/2001
3	Insulinoma 01/2013 - 07/2001
2	Insulin Resistance 12/2015 - 10/2007
2	Ketosis 06/2006 - 06/2002
1	Inborn Genetic Diseases (Disease, Hereditary) 06/2006
1	Acute Disease 06/2002
1	Autoimmune Diseases (Autoimmune Disease) 11/2001

Drug/Important Bio-Agent (IBA)

12	AutoantibodiesIBA 11/2021 - 07/2001
12	HLA-DQ Antigens (HLA-DQ)IBA 01/2018 - 01/2001
11	Insulin (Novolin)FDA Link 12/2015 - 08/2000
8	AntibodiesIBA 04/2013 - 08/2000
7	C-PeptideIBA 01/2017 - 08/2000
3	HLA-A Antigens (HLA-A)IBA 01/2018 - 04/2013
3	Complement System Proteins (Complement)IBA 12/2015 - 11/2005
3	Biomarkers (Surrogate Marker)IBA 12/2010 - 09/2001
3	Proteins (Proteins, Gene)FDA Link 03/2010 - 08/2000
2	HLA-B Antigens (HLA-B)IBA 01/2018 - 09/2013
2	Glucose (Dextrose)FDA LinkGeneric 12/2015 - 02/2015
2	ZincIBA 04/2013 - 03/2010
2	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2013 - 08/2000
2	AntigensIBA 01/2013 - 07/2001
2	Genetic Markers (Genetic Marker)IBA 11/2005 - 07/2001
1	EpitopesIBA 11/2021
1	Blood Glucose (Blood Sugar)IBA 12/2015
1	Zinc Transporter 8IBA 01/2013
1	Pancreatic HormonesIBA 10/2007
1	AdiponectinIBA 10/2007
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2007
1	Biological ProductsIBA 06/2006
1	micaIBA 01/2006
1	ProinsulinIBA 11/2005
1	HLA-DQA1 antigen (HLA DQA1)IBA 07/2004
1	Iodide Peroxidase (Deiodinase)IBA 11/2001
1	Immunoglobulin A (IgA)IBA 11/2001
1	islet cell antibodyIBA 08/2000

Therapy/Procedure

1	Injections 09/2009
1	Secondary Prevention 11/2005